Wisdom Pharmaceutical Co., Ltd.

Main purpose of the trial: To preliminarily study the pharmacokinetic characteristics of the test drug N2103 enteric-coated capsules (specification: 10 mg) and the control drug (specification: 5 mg) when taken orally in the fasting state in healthy participants, so as to provide a reference for the later development strategy. Secondary purpose of the trial: To preliminarily study the safety of the test drug N2103 enteric-coated capsules (specification: 10 mg) and the control drug (specification: 5 mg) in healthy participants.

The main purpose of the study is to study the pharmacokinetic characteristics of a single injection of the test preparation meloxicam nanocrystal injection (specification: 1 ml: 30 mg, held by Jiangsu Huiju Pharmaceutical Co., Ltd.) and the reference preparation meloxicam nanocrystal injection (Anjeso®, specification: 1 ml: 30 mg; licensed by Baudax Bio, Inc.) in healthy subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations by intravenous injection under fasting conditions. Secondary purpose of the study is to study the safety of the test preparation meloxicam nanocrystal injection (specification: 1 ml: 30 mg) and the reference preparation meloxicam nanocrystal injection (Anjeso®, specification: 1 ml: 30 mg) in healthy subjects.

To investigate the pharmacokinetic characteristics of a single oral administration of brepizole orodispersible film (experimental drug, strength: 2 mg) provided by Jiangsu Huiju Pharmaceutical Co., Ltd. or brepizole tablets (control drug, trade name: Rexulti®, strength: 2 mg) certified by Otsuka America Pharmaceutical, Inc. (USA) to healthy subjects under fasting and postprandial conditions, and to evaluate the relative bioavailability and safety of the two preparations, so as to provide a basis for the registration application of brepizole orodispersible film.